We describe the first case of bridge therapy in alpha-mannosidosis (AM) in an infant diagnosed at only 5 months of life who underwent enzyme replacement therapy (ERT) in the pre- and peri-transplant phases. Eight ERT infusions were administered before hematopoietic stem cell transplantation (HSCT) and continued for additional 90 days until complete engraftment. The clinical and laboratory data after 3 years post-HSCT show that the early combined intervention may reduce the disease progression and the urine and plasma content of mannosyl-oligosaccharides (OS) monitored by liquid chromatography tandem mass spectrometry (LC–MS/MS). This report highlights that early diagnosis and prompt initiation of such treatments in AM are the best chance to minimize the progression of symptoms.

Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, F., First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis, <<AMERICAN JOURNAL OF MEDICAL GENETICS. PART A>>, 2023; 191 (7): 1948-1952. [doi:10.1002/ajmg.a.63210] [https://hdl.handle.net/10807/244219]

First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis

Locatelli, Franco
Ultimo
2023

Abstract

We describe the first case of bridge therapy in alpha-mannosidosis (AM) in an infant diagnosed at only 5 months of life who underwent enzyme replacement therapy (ERT) in the pre- and peri-transplant phases. Eight ERT infusions were administered before hematopoietic stem cell transplantation (HSCT) and continued for additional 90 days until complete engraftment. The clinical and laboratory data after 3 years post-HSCT show that the early combined intervention may reduce the disease progression and the urine and plasma content of mannosyl-oligosaccharides (OS) monitored by liquid chromatography tandem mass spectrometry (LC–MS/MS). This report highlights that early diagnosis and prompt initiation of such treatments in AM are the best chance to minimize the progression of symptoms.
2023
Inglese
Santoro, L., Monachesi, C., Zampini, L., Padella, L., Galeazzi, T., Santori, E., Cordiali, R., Dardis, A., Catassi, C., Boccieri, E., Galaverna, F., Locatelli, F., First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis, <<AMERICAN JOURNAL OF MEDICAL GENETICS. PART A>>, 2023; 191 (7): 1948-1952. [doi:10.1002/ajmg.a.63210] [https://hdl.handle.net/10807/244219]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/244219
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact